Joyce O’Shaughnessy, MD:This patient is 62 years old and she noted a rapidly enlarging mass in her breast. When she went to her physician, she had a 6 cm mass in her breast and she had axillary adenopathy as well. And the biopsy showed grade 3 invasive ductal breast cancer that was strongly estrogen receptor-positive, progesterone receptor-negative, and HER2 [human epidermal growth factor receptor 2]-negative. Unfortunately, on staging evaluation, she had multiple liver metastasis at the time of presentation, no other sites of metastasis. And her liver function tests were mildly elevated. Her transaminases were mildly elevated. Bilirubin and alkaline phosphatase were normal, CBC [complete blood count] normal. Otherwise, a fairly healthy woman, no serious comorbidities. So she’s presenting with de novo metastatic disease, a grade 3 aggressive breast cancer, rapidly enlarging, already metastatic to the liver at the time of presentation.
When women present with de novo metastatic disease that’s estrogen receptor-positive, progesterone receptor-negative, HER2-negative, and grade 3 with liver metastasis at presentation, the median overall survival would probably be in the 2 to 3 year range. It’s quite variable, and it really does depend on the overall tempo of the disease. This woman’s tempo, unfortunately, was a rapidly growing mass and already multiple liver metastasis at the time of presentation. Things are changing for the better with regard to our therapies. But generally speaking, the median overall survival is probably in the range of 2 to 3 years for this woman.
Transcript edited for clarity.
Case: A 62-Year-Old Woman WithDe NovoInvasive Ductal Carcinoma
Therapy Changes for Metastases and Toxicity Discussed in Breast Cancer
September 5th 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.
Read More
Participants Consider the Necessity of Chemo in HER2+ Breast Cancer
August 22nd 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
FDA Lifts Partial Clinical Hold on Phase 1 YL202 Trial in NSCLC and Breast Cancer
August 19th 2024The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.
Read More